Company: BIAF
Filing Date: 2025-08-22
Form Type: DRS
Source: 0001641172-25-025247
Chunk: 21

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-08-22
Form: DRS
Chunk 21
---
 warrants, at the reduced exercise price of $ 0.23per share, and our receipt of approximately $149,500 in proceeds upon such exercise and (ii) an aggregate of 450,000shares of Common Stock that we issued on August 5, 2024, upon the exercise of warrants, at the reduced exercise price of $ 0.23per share, and our receipt of approximately $103,500 in proceeds upon such exercise, (iii) an aggregate of 9,071 shares of Common Stock were sold under the Company’s ATM Agreement, and our receipt of approximately $3,000 in proceeds upon the sale, and (iv) an aggregate of 990 shares of Series B Convertible Preferred Stock were issued on August 13, 2025, and our receipt of approximately $990,000 in proceeds upon issuance.

Dilution represents the difference between the amount per share paid by purchasers in this offering and the pro forma as adjusted net tangible book value per share of Common Stock after the offering. After giving effect to the issuance and sale of _________ shares of Common Stock (or Pre-Funded Warrants in lieu thereof) in this offering at an assumed public offering price of $___ per share, and after deducting estimated underwriting discounts and commissions and estimated offering expenses, our pro forma as adjusted net tangible book value as of June 30, 2025, would have been $ ___ per share. This represents an immediate decrease in net tangible book value of $____ per share to existing stockholders and an immediate dilution in net tangible book value of $____ per share to purchasers of Common Stock in this offering, based on an assumed public offering price of $_____ per share. The following table illustrates this per share dilution:

| Assumed public offering price per share of Common Stock                                         
 Historical net tangible book value per share as of June 30, 2025                                |     |   | (0.15 | ) |
|:------------------------------------------------------------------------------------------------|:----|:--|:------|:--|
| Pro forma net tangible book value per share                                                     |     | $ | (0.14 | ) |
| Increase in pro forma net tangible book value per share attributable to this offering           |     | $ |       |   |
| Pro forma as adjusted net tangible book value per share after giving effective to this offering |     | $ |       |   |
| Dilution per share to the new investor in this offering                                         |     | $ |       |   |

The number